Page 13 - hypertension_newsletter8

REFLECTIONS
Hypertension
Hypertension Global Newsletter #8 2025

All 30 studies reported a change in SBP, with a mean reduction of –3.37 mmHg (95% CI –3.95 to –2.80), and 29 studies reported
a change in DBP, with a mean reduction of –1.05 mmHg (95% CI –1.46 to –0.65). This effect was generally consistent across Hypertension
subgroups (patients with and without diabetes mellitus) regardless of treatment duration, formulation, and route of administration,
although exenatide did not show a significant reduction in DBP. Notably, oral GLP-1 RAs showed a greater reduction in both SBP and
DBP compared to subcutaneous formulations.

Random effects meta-regression indicated that greater weight
loss was associated with larger reductions in both SBP and CLINICAL PEARLS FROM THE FACULTY
DBP. For every 1 kg decrease in weight, SBP reduction
increases by 0.24 mmHg (95% CI 0.05–0.43, P = 0.017) and
DBP reduction increases by 0.19 mmHg (95% CI 0.07–0.32, P
= 0.004). Baseline characteristics did not significantly correlate
with the extent of BP reduction.

The findings of this meta-analysis suggest that GLP-1 RAs offer
a significant benefit in reducing blood pressure in overweight
or obese individuals, regardless of their diabetic status. Given
the high prevalence of hypertension in this population, the study
supports the use of GLP-1 RAs for glycaemic control and weight WATCH
loss, as well as an adjunct therapy for managing hypertension VIEW COMMENTARY FROM PROF.
in this patient population. The authors highlight the need for TSABEDZE ON HOW THE FINDINGS
further research to investigate the longitudinal relationship of IMPACT CLINICAL PRACTICE.
weight loss from GLP-1 RA use with extent of BP reduction, the
effect of GLP-1 RA-associated BP reduction on cardiovascular
outcomes, and the BP-lowering potential of specific GLP-1 RA CLICK HERE
formulations, and their different routes of administration. FOR THE LINK TO FULL ARTICLE

TABLE OF CONTENTS